CC-486 Improves Myelodysplastic Syndromes Patient’s Transfusion Independence But With Significant Adverse Reactions
source: pixabay.com

CC-486 Improves Myelodysplastic Syndromes Patient’s Transfusion Independence But With Significant Adverse Reactions

  Results of a Phase III study of CC-486 (oral form of azacitidine) showed a significant improvement for older patients who had been transfusion dependent. The results were favorable when…

Continue Reading CC-486 Improves Myelodysplastic Syndromes Patient’s Transfusion Independence But With Significant Adverse Reactions
Planned Phase 2 Trial of ANVS401 for Alzheimer’s and Parkinson’s Moving Forward
source: pixabay.com

Planned Phase 2 Trial of ANVS401 for Alzheimer’s and Parkinson’s Moving Forward

As reported in Parkinson's News Today, an investigational therapy to treat patients with Alzheimer's disease and Parkinson’s disease has had its Phase 2 trial approved by the central institutional review…

Continue Reading Planned Phase 2 Trial of ANVS401 for Alzheimer’s and Parkinson’s Moving Forward
How to Make Better Decisions, Even with Anxiety
For those who don't know, "word clouds" are graphics created by analyzing the words most commonly used to describe something. The size of the words indicate how frequently they are used (the largest word is the one that's most frequently used). Source: Pixabay.com

How to Make Better Decisions, Even with Anxiety

  It's no secret to anybody that knows me: I struggle with anxiety, and have for as long as I can remember. I was first medicated for anxiety and depression…

Continue Reading How to Make Better Decisions, Even with Anxiety
Investigational Waldenström’s Macroglobulinemia Treatment Earns Orphan Drug Designation
source: pixabay.com

Investigational Waldenström’s Macroglobulinemia Treatment Earns Orphan Drug Designation

According to a story from BioSpace, the biotechnology company Ascentage Pharma has just announced that it has been given Orphan Drug designation from the US Food and Drug Administration (FDA).…

Continue Reading Investigational Waldenström’s Macroglobulinemia Treatment Earns Orphan Drug Designation
Problems with Eyesight Prevalent in Parkinson’s Disease as Patients Age, Study Finds
source: pixabay.com

Problems with Eyesight Prevalent in Parkinson’s Disease as Patients Age, Study Finds

According to a story from Parkinson's News Today, older patients with Parkinson's disease appear to have a higher than average rates of vision problems. These issues are also associated with…

Continue Reading Problems with Eyesight Prevalent in Parkinson’s Disease as Patients Age, Study Finds
Alternate Method for Staging Chronic Kidney Disease Could be Cheaper and More Widely Available
source: pixabay.com

Alternate Method for Staging Chronic Kidney Disease Could be Cheaper and More Widely Available

According to a story from Physician's Weekly, while measuring the concentration of albumin (albuminuria) is widely considered the standard method for staging and screening for chronic kidney disease, a different…

Continue Reading Alternate Method for Staging Chronic Kidney Disease Could be Cheaper and More Widely Available
The FDA Grants Orphan Drug Designation to Oncternal Therapeutics for the Treatment of Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma
source: pixabay.com

The FDA Grants Orphan Drug Designation to Oncternal Therapeutics for the Treatment of Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma

  Orphan drug designations are granted by the FDA to drugs and biologics that are developed for the treatment of rare diseases.  According to a recent article in Biospace, Oncternal…

Continue Reading The FDA Grants Orphan Drug Designation to Oncternal Therapeutics for the Treatment of Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma
Ankylosing Spondylitis Treatment Approved but Not Yet Available
https://pixabay.com/en/approved-pass-ok-approval-symbol-1726357/

Ankylosing Spondylitis Treatment Approved but Not Yet Available

According to Ankylosing Spondylitis News, a new treatment, Hulio, has been approved by the FDA. It is a treatment for ankylosing spondylitis and other inflammatory disorders. Although it has been…

Continue Reading Ankylosing Spondylitis Treatment Approved but Not Yet Available